The American Society of Dermatopathology

Special Topics

Essentials of Oncodermatopathology: Cutaneous Reactions to Novel Cancer Therapies and Beyond

Friday, October 22
8:00 a.m. - 12:30 p.m. Central Time

Course Director
Emily Y. Chu, MD, PhD
University of Pennsylvania

AMA PRA Category 1 CreditsTM

Advances in treatments for cancer with small molecule inhibitors (Nibs) and monoclonal antibodies (Mabs) have led to a diverse array of cutaneous adverse reactions. Dermatopathologic diagnosis of these cutaneous adverse reactions poses challenges due to the development of hundreds of novel, clinically available cancer agents and the continued emergence of new adverse reactions to these types of therapies. Knowledge of the range of cutaneous adverse reactions and accurate diagnosis is essential for optimal patient care. This course will present the spectrum of cutaneous adverse reactions to novel cancer therapies, including tyrosine kinase inhibitors and immunotherapy agents, among others. In addition, topics highly relevant to the care of cancer patients will be discussed, including assessment of ‎immunotherapy responses in the skin and the histopathology of cutaneous graft versus host disease.‎ 

Faculty and Course Outline:

8:00 a.m. - 8:05 a.m. 

Emily Y. Chu, MD, PhD
University of Pennsylvania
8:05 a.m. - 8:35 a.m.

Immunotherapy Responses in the Skin and Beyond
Janis M. Taube, MD
Johns Hopkins Hospital
8:35 a.m. - 9:05 a.m.

Cutaneous Adverse Reactions to Cancer Therapy with Small Molecule Inhibitors (Nibs)
Jonathan L. Curry, MD
MD Anderson Cancer Center
9:05 a.m. - 9:30 a.m.

Approach to Immune Checkpoint Inhibitor Reactions
Emily Y. Chu, MD, PhD
University of Pennsylvania
9:30 a.m. - 10:00 a.m.

Skin Adverse Reactions of Newer Treatments for Hematologic Malignancies
Kerri E. Rieger, MD, PhD
Stanford University
10:00 a.m. - 10:30 a.m. Break
10:30 a.m. - 11:00 a.m.

Graft-versus-Host Disease
Jennifer M. McNiff, MD
Yale University
11:00 a.m. - 11:30 a.m.

Pseudosarcomatous Proliferations in Tumor Syndromes
Ryanne Brown, MD, MBA
Stanford University
11:30 a.m. - Noon

Inpatient Oncodermatopathology
Cuong V. Nguyen, MD
Northwestern University
Noon - 12:30 p.m. Q&A

Learning Objectives
Upon completion of this course, participants should be able to:

  • Identify common cutaneous adverse reactions associated with newer cancer therapies.
  • Discuss diagnostic features of neutrophilic dermatoses.
  • Recognize key features of opportunistic infections in cancer patients.